Table 3. Comparing the relative efficacy of interventions with respect to two-year survival status using pairwise and network meta-analysis.
| TACE | TACE +EBRT | TACE +HIFU | TACE +PEI | TACE +RFA | TACE +RT | TACE +SOR | TARE -90Y | DEB -TACE | PAI | PEI | RFA | RT | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TACE | 0.71 (0.59, 0.83) | 0.25 (0.22, 0.28) | 0.51 (0.46, 0.56) | 0.53 (0.42, 0.63) | 0.53 (0.47, 0.59) | 0.55 (0.50, 0.60) | 0.87 (0.80, 0.94) | 0.52 (0.47, 0.57) | - | - | 0.90 (0.80, 0.99) | 0.44 (0.34, 0.54) | |
| TACE+EBRT | 0.71 (0.33, 1.53) | - | - | - | - | - | - | - | - | - | - | - | |
| TACE+HIFU | 0.31 (0.18, 0.54) | 0.44 (0.17, 1.13) | - | - | - | - | - | - | - | - | - | - | |
| TACE+PEI | 0.76 (0.55, 1.04) | 1.07 (0.46, 2.45) | 2.41 (1.28, 4.53) | - | - | - | - | - | - | 2.02 (1.77, 2.35) | - | - | |
| TACE+RFA | 0.46 (0.31, 0.67) | 0.64 (0.27, 1.52) | 1.45 (0.75, 2.83) | 0.60 (0.38, 0.97) | - | - | - | - | - | - | 1.90 (1.66, 2.22) | - | |
| TACE+RT | 0.44 (0.29, 0.67) | 0.62 (0.26, 1.49) | 1.40 (0.71, 2.78) | 0.58 (0.34, 0.99) | 0.96 (0.55, 1.70) | - | - | - | - | - | - | 5.56 (4.44, 7.41) | |
| TACE+SOR | 0.67 (0.47, 0.95) | 0.94 (0.40, 2.18) | 2.12 (1.11, 4.05) | 0.88 (0.55, 1.42) | 1.46 (0.87, 2.46) | 1.52 (0.88, 2.61) | - | - | - | - | - | - | |
| TARE-90Y | 0.87 (0.59, 1.28) | 1.23 (0.52, 2.90) | 2.78 (1.43, 5.40) | 1.15 (0.70, 1.90) | 1.91 (1.11, 3.29) | 1.98 (1.12, 3.50) | 1.31 (0.78, 2.20) | - | - | - | - | - | |
| DEB-TACE | 0.62 (0.46, 0.84) | 0.87 (0.38, 2.00) | 1.98 (1.06, 3.68) | 0.82 (0.53, 1.27) | 1.36 (0.83, 2.22) | 1.41 (0.84, 2.36) | 0.93 (0.59, 1.47) | 0.71 (0.44, 1.16) | - | - | - | - | |
| PAI | 1.12 (0.46, 2.70) | 1.58 (0.49, 5.07) | 3.56 (1.26, 10.03) | 1.48 (0.60, 3.63) | 2.45 (0.99, 6.04) | 2.54 (0.96, 6.74) | 1.68 (0.65, 4.33) | 1.28 (0.49, 3.35) | 1.80 (0.71, 4.57) | 1.78 (0.93, 1.60) | - | - | |
| PEI | 1.32 (0.90, 1.93) | 1.85 (0.79, 4.37) | 4.19 (2.16, 8.13) | 1.74 (1.15, 2.64) | 2.88 (1.88, 4.41) | 2.99 (1.70, 5.26) | 1.97 (1.18, 3.31) | 1.51 (0.88, 2.59) | 2.12 (1.31, 3.44) | 1.18 (0.53, 2.60) | 0.43 (0.35, 0.50) | - | |
| RFA | 0.76 (0.53, 1.08) | 1.07 (0.46, 2.49) | 2.42 (1.27, 4.62) | 1.00 (0.65, 1.55) | 1.66 (1.21, 2.28) | 1.73 (1.00, 2.98) | 1.14 (0.69, 1.87) | 0.87 (0.52, 1.47) | 1.22 (0.77, 1.94) | 0.68 (0.29, 1.61) | 0.58 (0.42, 0.80) | - | |
| RT | 1.03 (0.57, 1.86) | 1.45 (0.55, 3.82) | 3.27 (1.47, 7.32) | 1.36 (0.69, 2.67) | 2.25 (1.11, 4.57) | 2.34 (1.29, 4.23) | 1.54 (0.77, 3.07) | 1.18 (0.58, 2.39) | 1.65 (0.85, 3.21) | 0.92 (0.32, 2.66) | 0.78 (0.39, 1.58) | 1.35 (0.68, 2.70) |
1. The cells in blue are results of pair-wise meta-analysis and the column treatment is compared with the row treatment. The results are presented by hazard ratio (HR) and 95% credible interval (CrI). The cells in red are results of network meta-analysis and the row treatment is compared with the column treatment. The results are presented by hazard ratio (HR) and 95% credible interval (CrI).
2. TACE: transcatheter arterial chemoembolization; EBRT: external-beam radiation therapy; HIFU: high intensity focused ultrasound; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation; RT: radiotherapy; SOR: sorafenib; TARE-90Y: yttrium-90 radioembolization; DEB-TACE: drug-eluting beads-transcatheter arterial chemoembolization; PAI: percutaneous acetic acid injection.